Late last week Bristol Myers Squibb (BMY) got a nice 8% boost after sharing news that it gained approval from the Food and Drug Administration (FDA) for its schizophrenia drug. The stock has cooled off since and is up just shy of 4% over the past week, but it has been on a serious [...]
Eli Lilly & Co. (LLY) is up more than 8% so far Thursday morning after reporting second-quarter earnings that easily surpassed the Wall Street consensus. The company also raised its guidance for the full year. The drugmaker posted adjusted earnings per share of $3.92, well ahead of the $2.60 that was expected by analysts. [...]
Merck (MRK) received US FDA approval on Tuesday after the market’s close for Winrevair to treat pulmonary arterial hypertension (PAH), causing the stock to climb 4.6% pre-market. The company’s market cap is around $332.7 billion, indicating any notable movement is a result of a significant event, so the approval demonstrates a pretty big win [...]
Johnson & Johnson (JNJ) is known for baby products and the single-shot COVID-19 vaccine, making it a significant booster if you invested before the pandemic. However, following recent lawsuits, JNJ settled to pay $700 million following an investigation over its baby powder, while the COVID-19 vaccine was discontinued in the US, leading to an [...]
Pfizer (PFE) fell 9% in Wednesday morning trading after the company’s weak forecast for 2024 left much to be desired in the eyes of investors and analysts alike. The stock is headed toward a 10-year low, and has now shed 50% of its value in the last year alone. The drugmaker has been steadily [...]
Yesterday, we highlighted Pfizer’s challenges in pivoting as a post-pandemic company. Today, its competitor Johnson & Johnson (JNJ) reported earnings itself. But, Johnson & Johnson painted an entirely different picture - beating out the earnings estimate on the top and bottom line while raising the forecast for the remainder of the year. The company [...]
Pfizer (PFE) ended last week on a sour note, announcing after the market closed on Friday that it will cut $9 billion from its sales outlook. And yet, the stock is up more than 5% so far in Monday morning’s trading session. The full-year EPS has been adjusted to $1.45 to $1.65 on revenue [...]
Johnson & Johnson (JNJ) has had its ups and downs over the past few months, but it appears as if steady growth is ahead. The company has boosted its previous guidance for the year after Thursday’s earnings report came in well above analyst expectations. Johnson & Johnson saw sales growth of 6.3% for the [...]
While much of the recent focus within the stock market has been placed on the AI trend, one stock in the pharmaceutical industry has been on a surge so far this year: Eli Lilly (LLY). The stock sat at just $311/share at the start of March. And today, the stock sits at $452/share. But, [...]
